MedTrace Logo

Artemether/Lumefantrine and Vivax Malaria

NCT01625871 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2013-01-17

No results posted yet for this study

Summary

The cure rate of artemether/lumefantrine in the treatment of vivax malaria.

Conditions

  • Vivax Malaria

Interventions

DRUG

tablets artemether/lumefantrine

six doses of oral tablets of artemether/lumefantrine

Sponsors & Collaborators

  • University of Kassala, Sudan

    collaborator OTHER

  • University of Khartoum

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Sudan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01625871 on ClinicalTrials.gov